We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott Laboratories (ABT - Free Report) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.
Abbott Labs reports its diversified business in four segments – namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. The company has reshaped its portfolio through strategic acquisitions/divestitures in recent times. It has also been taking strategic steps to expand its footprint in the growing geographies and investing in R&D, which has resulted in numerous new product launches across its businesses.
In Feb 2015, Abbott completed the sale of its branded generics pharmaceuticals business in developed markets. Realignment of the EPD division through acquisitions in Latin America and Russia, along with business divestitures in developed markets, has positioned the company well for the coming quarters. However, unfavorable movement in foreign currency rates is affecting the top line adversely.
Abbott Labs has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 3.2%.
Currently, Abbott Labs has a Zacks Rank #3 (Hold). We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Our consensus called for EPS of 53 cents per share, while the company reported EPS of 55 cents (from continuing operations excluding one-time items).
Revenue: Abbott Labs posted revenues of $5.33 billion, above our expectations of $5.26 billion.
Key Stats: The recent launches of FreeStyle Libre, MitraClip, Absorb and Symfony have boosted the performance. Foreign currency exchange rate movements negatively impacted sales by 3.2%. The company expects 2016 earnings per share in the range of $2.14 per share to $2.24 per share (excluding specified items).
Check back later for our full write up on this Abbott Labs earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Abbott (ABT) Beats on Earnings & Sales in Q2
Abbott Laboratories (ABT - Free Report) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.
Abbott Labs reports its diversified business in four segments – namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. The company has reshaped its portfolio through strategic acquisitions/divestitures in recent times. It has also been taking strategic steps to expand its footprint in the growing geographies and investing in R&D, which has resulted in numerous new product launches across its businesses.
In Feb 2015, Abbott completed the sale of its branded generics pharmaceuticals business in developed markets. Realignment of the EPD division through acquisitions in Latin America and Russia, along with business divestitures in developed markets, has positioned the company well for the coming quarters. However, unfavorable movement in foreign currency rates is affecting the top line adversely.
Abbott Labs has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 3.2%.
ABBOTT LABS Price and EPS Surprise
ABBOTT LABS Price and EPS Surprise | ABBOTT LABS Quote
Currently, Abbott Labs has a Zacks Rank #3 (Hold). We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Our consensus called for EPS of 53 cents per share, while the company reported EPS of 55 cents (from continuing operations excluding one-time items).
Revenue: Abbott Labs posted revenues of $5.33 billion, above our expectations of $5.26 billion.
Key Stats: The recent launches of FreeStyle Libre, MitraClip, Absorb and Symfony have boosted the performance. Foreign currency exchange rate movements negatively impacted sales by 3.2%. The company expects 2016 earnings per share in the range of $2.14 per share to $2.24 per share (excluding specified items).
Check back later for our full write up on this Abbott Labs earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>